RNTX — Rein Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$0.76
+$0.00 (+0.56%)
Rein Therapeutics Inc (RNTX) is a biotechnology company listed on NASDAQ. It is led by Cory M. Hogaboam Ph.D., based in 12407 N. Mopac Expy., Austin, TX, United States, 78758, with about 10 employees. Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Latest reported RNTX revenue for 2025-09-30 was $0. Net income was -$17.9M. RNTX currently screens at market cap $80.6M.
Use this RNTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RNTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RNTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Rein Therapeutics Inc even when a live quote feed is slow.
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
RNTX Key Statistics
Market Cap
$80.62M
Volume
276,751
Previous Close
$0.80
Day Range
$0.77 – $0.82
P/B Ratio
28.17
EPS
-$3.51
Revenue
$0.00
Net Income
-$62.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
10
RNTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$62.88M | -$15.73M | -$27.33M | -$26.16M |
| EPS (Diluted) | -$3.51 | -$3.42 | -$6.02 | -$5.89 |
Total Assets
$62.19M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$12.87M
Operating Cash Flow
-$22.29M
Free Cash Flow
$0.00
Rein Therapeutics Inc Company Information
- Chief Scientific Officer
- Cory M. Hogaboam Ph.D.
- Headquarters
- 12407 N. Mopac Expy., Austin, TX, United States, 78758
- Website
- www.reintx.com
- Phone
- 737 802 1989
- IPO / Founded
- 1986-03-12
- Sector
- Healthcare
- Industry
- Biotechnology